New Board member
We warmly welcome Filip Bergquist as a new Board member. He will be replacing Gesine Paul-Visse as SWEMODIS representative.
You can read more about Filip on the board page.
We warmly welcome Filip Bergquist as a new Board member. He will be replacing Gesine Paul-Visse as SWEMODIS representative.
You can read more about Filip on the board page.

Serra GP, Guillaumin A, Vlcek B, Delgado-Zabalza L, Ricci A, Rubino E, Dumas S, Baufreton J, Georges F, Wallén-Mackenzie Å#.
A role for the subthalamic nucleus in aversion learning.
Cell Reports. 42. 113328. November 28. 2023.
https://doi.org/10.1016/j.celrep.2023.113328

Vlcek B, Dumas S, Rubino E, Ekmark-Lewén S, Ingelsson M, Wallén-Mackenzie Å#.
Aldh1a1 and additional markers of dopamine cell heterogeneity in substantia nigra and ventral tegmental area identified as preserved in two transgenic alpha-synuclein mouse models of neurodegenerative disease.
Explor Neuroprot Ther. 2023; 3:299-327.
https://doi.org/10.37349/ent.2023.00053
We hope you aren’t missing out on our awesome archive of webinar lectures. We wish to provide you with valuable insights and knowledge, and the latest from the fascinating world of the basal ganglia.
But we want to hear from you, too! Please let us know what more you would like to hear about or the specific researchers and experts you’d like to hear from. Your input helps us tailor our future content to your interests and needs.
Here’s a taste of what our archive has to offer:
Dive into our archive, and let us know your thoughts and suggestions. We look forward to hearing from you and continuing to provide valuable content for your interests.
Explore Our Archive of Webinar Lectures Read More »
All Members are welcome to our annual meeting scheduled for November 24 at 15:00-15:30 CET.
Please find the agenda here: https://swebags.ebrains.se/forums/topic/annual-meeting-2023/
New recordings from the latest webinar are now available in the webinar archive:
Dopamine waves as a mechanism for spatiotemporal credit assignment with Arif Hamid
Traveling waves of acetylcholine and dopamine release in the striatum with Josh Goldberg

Did you miss the May webinar? No worries; it is now uploaded to the webinar archive. The webinars now take a short break and will be back again on August 25 with lectures by Arif Hamid and Josh Goldberg
May webinar and summer break Read More »
We have now reached a new milestone regarding memberships. Currently have 300+ members representing 110 different organisations in 25 countries have joined SWEBAGS!
We are so happy that so many have joined our society and hope you all utilize this big gathering of colleagues from all around the world by interacting and sharing news and articles and watching more than 40 hours of webinars from leading colleagues…
Please help us grow further by spreading the word to your colleagues.

The latest recording from the webinar on Basal Ganglia in addiction is now available.

A new recording added to the archive Read More »
Author: Espa E, Song L, Skovgård K, Fanni S, Cenci MA.
Abstract:
Background: Current models of L-DOPA-induced dyskinesia (LID) are obtained by treating dopamine-depleted animals with L-DOPA. However, patients with LID receive combination therapies that often include dopamine agonists.
Objective: Using 6-hydroxydopamine-lesioned rats as a model, we aimed to establish whether adjunct treatment with the D2/3 agonist ropinirole impacts on patterns of LID-related neuroplasticity and drug responses.
Methods: Different regimens of L-DOPA monotreatment and L-DOPA-ropinirole cotreatment were compared using measures of hypokinesia and dyskinesia. Striatal expression of ∆FosB and angiogenesis markers were studied immunohistochemically. Antidyskinetic effects of different drug categories were investigated in parallel groups of rats receiving either L-DOPA monotreatment or L-DOPA combined with ropinirole.
Results: We defined chronic regimens of L-DOPA monotreatment and L-DOPA-ropinirole cotreatment inducing overall similar abnormal involuntary movement scores. Compared to the monotreatment group, animals receiving the L-DOPA-ropinirole combination exhibited an overall lower striatal expression of ∆FosB with a distinctive compartmental distribution. The expression of angiogenesis markers and blood-brain barrier hyperpermeability was markedly reduced following L-DOPA-ropinirole cotreatment vs L-DOPA monotreatment. Significant group differences were moreover detected upon comparing the response to candidate antidyskinetic drugs. In particular, compounds modulating D1 receptor signaling had a stronger effect in the L-DOPA-only group, whereas both amantadine and the selective NMDA antagonist MK801 produced a markedly larger antidyskinetic effect in L-DOPA-ropinirole cotreated animals.
Conclusions: Cotreatment with ropinirole altered LID-related neuroplasticity and pharmacological response profiles. The impact of adjuvant dopamine agonist treatment should be taken into consideration when investigating LID mechanisms candidate interventions in both clinical and experimental settings.
The abstract submission deadline and early-bird registration time has been prolonged to January 31st 2023.